NEW YORK (GenomeWeb) – Qiagen today said that it has signed a master collaboration agreement to develop and commercialize companion diagnostics for existing Novartis products as well as compounds in Novartis' development pipeline.

The non-exclusive deal is the ninth master framework agreement for Qiagen and covers all Qiagen platforms, indications, or biomarkers, it said. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.